相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cystic fibrosis F508del carriers and cancer risk: Results from the UK Biobank
Zhuqing Shi et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Modulators of Neuroinflammation Have a Beneficial Effect in a Lafora Disease Mouse Model
Belen Molla et al.
MOLECULAR NEUROBIOLOGY (2021)
Propranolol Reduces the Development of Lesions and Rescues Barrier Function in Cerebral Cavernous Malformations A Preclinical Study
Joppe Oldenburg et al.
STROKE (2021)
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K. Choueiri et al.
NATURE MEDICINE (2021)
Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models (vol 131, e144893, 2021)
Wenqing Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Drug databases and their contributions to drug repurposing
Yosef Masoudi-Sobhanzadeh et al.
GENOMICS (2020)
How many rare diseases are there?
Melissa Haendel et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Propranolol for infantile hepatic hemangioendothelioma: Clinical evaluation of drug efficacy and safety using a single-center patient cohort
Ruicheng Tian et al.
ANNALS OF HEPATOLOGY (2020)
Cystic Fibrosis, CFTR, and Colorectal Cancer
Patricia Scott et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease–associated renal cell carcinoma.
Eric Jonasch et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension
Jacques W. M. Lenders et al.
JOURNAL OF HYPERTENSION (2020)
Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial
Silvia Lanfranconi et al.
TRIALS (2020)
Review of Pharmacological Strategies with Repurposed Drugs for Hereditary Hemorrhagic Telangiectasia Related Bleeding
Virginia Albinana et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia
Marie E. Faughnan et al.
ANNALS OF INTERNAL MEDICINE (2020)
PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma-a proof of principle study
Kimberley M. Heinhuis et al.
BMJ OPEN (2020)
Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel-Lindau Disease
Virginia Albinana et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Topical Propranolol Improves Epistaxis Control in Hereditary Hemorrhagic Telangiectasia (HHT): A Randomized Double-Blind Placebo-Controlled Trial
Meir Mei-Zahav et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Mapping endothelial-cell diversity in cerebral cavernous malformations at single-cell resolution
Fabrizio Orsenigo et al.
ELIFE (2020)
Complex Solid and Cystic Breast Cancer: A Series of Six Case Reports
Nishi Mehta et al.
JOURNAL OF RADIOLOGY CASE REPORTS (2020)
Sclerotherapy and Topical Nasal Propranolol: An Effective and Safe Therapy for HHT-Epistaxis
Santos Esteban-Casado et al.
LARYNGOSCOPE (2019)
The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease
A. M. Cuesta et al.
SCIENTIFIC REPORTS (2019)
The burden of rare diseases
Carlos R. Ferreira
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2019)
Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: phase III clinical trial
Beatriz Gonzalez-Rodriguez et al.
BMJ OPEN OPHTHALMOLOGY (2019)
Infantile hemangiomas: what have we learned from propranolol?
Rachael Hagen et al.
CURRENT OPINION IN PEDIATRICS (2018)
Efficacy of Propranolol Between 6 and 12 Months of Age in High-Risk Infantile Hemangioma
Eulalia Baselga et al.
PEDIATRICS (2018)
Infantile hemangioma: pathogenesis and mechanisms of action of propranolol
Anita Rotter et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2017)
Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report
Meir Mei-Zahav et al.
JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2017)
Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease
Virginia Albinana et al.
ORPHANET JOURNAL OF RARE DISEASES (2017)
Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?
Yanqing Huang et al.
SCIENCE CHINA-LIFE SCIENCES (2017)
Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation
Naikhoba C. O. Munabi et al.
STEM CELLS TRANSLATIONAL MEDICINE (2016)
Topical application of timolol decreases the severity and frequency of epistaxis in patients who have previously undergone nasal dermoplasty for hereditary hemorrhagic telangiectasia
Keiichi Ichimura et al.
AURIS NASUS LARYNX (2016)
Propranolol stops progressive multiple cerebral cavernoma in an adult patient
Matthias Reinhard et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2016)
Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data
Margaret A. Horne et al.
LANCET NEUROLOGY (2016)
Propranolol Treatment of Cavernous Malformations with Symptomatic Hemorrhage
Joseph M. Zabramski et al.
WORLD NEUROSURGERY (2016)
Computational and Practical Aspects of Drug Repositioning
Tudor I. Oprea et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2015)
Propranolol Reduces Cancer Risk A Population-Based Cohort Study
Ping-Ying Chang et al.
MEDICINE (2015)
A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma
C. Leaute-Labreze et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients
Virginia Albinana et al.
ORPHANET JOURNAL OF RARE DISEASES (2015)
VHL, the story of a tumour suppressor gene
Lucy Gossage et al.
NATURE REVIEWS CANCER (2015)
β-adrenergic receptor antagonists inhibit vasculogenesis of embryonic stem cells by downregulation of nitric oxide generation and interference with VEGF signalling
Fatemeh Sharifpanah et al.
CELL AND TISSUE RESEARCH (2014)
Hemangioblastomas in the elderly: Epidemiology and clinical characteristics
Charles D. Kassardjian et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2014)
Nervous system involvement in von Hippel-Lindau disease: pathology and mechanisms
Alexander O. Vortmeyer et al.
ACTA NEUROPATHOLOGICA (2013)
Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants <4months of age
C. Leaute-Labreze et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Von Hippel-Lindau: How a rare disease illuminates cancer biology
Stephane Richard et al.
SEMINARS IN CANCER BIOLOGY (2013)
Von Hippel-Lindau Disease: A Genetic and Clinical Review
Nour Maya N. Haddad et al.
SEMINARS IN OPHTHALMOLOGY (2013)
Topical timolol for the treatment of epistaxis in hereditary hemorrhagic telangiectasia
Scott E. Olitsky
AMERICAN JOURNAL OF OTOLARYNGOLOGY (2012)
Systemic VHL gene functions and the VHL disease
Hannah L. Bader et al.
FEBS LETTERS (2012)
Correlation of expression pattern of aquaporin-1 in primary central nervous system tumors with tumor type, grade, proliferation, microvessel density, contrast-enhancement and perilesional edema
Prabal Deb et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2012)
Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia
Virginia Albinana et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Initial Experience Using Propranolol as an Adjunctive Treatment in Children With Aggressive Recurrent Respiratory Papillomatosis
Stephen Maturo et al.
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY (2011)
von Hippel-Lindau disease: A clinical and scientific review
Eamonn R. Maher et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2011)
Hereditary hemorrhagic telangiectasia: An overview of diagnosis, management, and pathogenesis
Jamie McDonald et al.
GENETICS IN MEDICINE (2011)
Antiangiogenic effects of β2-adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy
Davide - Martini et al.
JOURNAL OF NEUROCHEMISTRY (2011)
Functional and Transcriptional Induction of Aquaporin-1 Gene by Hypoxia; Analysis of Promoter and Role of Hif-1α
Irene Abreu-Rodriguez et al.
PLOS ONE (2011)
Systematic Drug Repositioning Based on Clinical Side-Effects
Lun Yang et al.
PLOS ONE (2011)
A Randomized Controlled Trial of Propranolol for Infantile Hemangiomas
Marcia Hogeling et al.
PEDIATRICS (2011)
Propranolol in the treatment of infantile hemangioma: clinical effectiveness, risks, and recommendations
I. Sanchez-Carpintero et al.
ACTAS DERMO-SIFILIOGRAFICAS (2011)
Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action
C. H. Storch et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
A Review on Clinical Management and Pharmacological Therapy on Hereditary Haemorrhagic Telangiectasia (HHT)
Roberto Zarrabeitia et al.
CURRENT VASCULAR PHARMACOLOGY (2010)
Correlation between the expression of aquaporin 1 and hypoxia-inducible factor 1 in breast cancer tissues
Tiejun Yin et al.
JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES (2008)
Propranolol for severe hemangiomas of infancy
Christine Leaute-Labreze et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Molecular basis of the VHL hereditary cancer syndrome
WG Kaelin
NATURE REVIEWS CANCER (2002)
分享论文
